Skip to main content

Advertisement

Table 1 Comparison among the Best Overall Response Rate, the Disease Control Rate, and the duration of response of the three randomized phase II-III studies which utilized ipilimumab (MDX010-08, MDX010-20, and CA184-024)

From: Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application

  MDX010-08 MDX010-20 CA184-024
  DTIC + Ipi Ipi Ipi + gp100 Ipi gp100 DTIC + Ipi DTIC
Patients (N.) (35) (37) (403) (137) (136) (250) (252)
BORR 14.3% 5.4% 5.7% 10.9% 1.5% 15.2% 10.3%
DCR 37.1% 21.6% 20.1% 28.5% 11.0% 33.2% 30.1%
Median Duration of BOR in months (CI) 5.7* (0.7-19.2) 10.8* (3.0-25.4) 11.5 (5.5-NR) NR (28.1-NR) NR (2.0-NR) 19.3 (not reported) 8.1 (not reported)
  1. *this value indicated the major durable DCR (≥ 24 weeks)
  2. DTIC = dacarbazine
  3. Ipi = ipilimumab
  4. BORR = Best Overall Response Rate = Complete Remission + Partial Remission
  5. DCR = Disease Control Rate = Complete Remission + Partial Remission + Stable Disease
  6. BOR = Best Overall Response
  7. CI = Confidence Interval
  8. NR = Not Reached